Form 8-K ARRAY BIOPHARMA INC For: Jan 29
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Array Biopharma (ARRY) Tops Q2 EPS by 12c; CFO Resigns; Updates on Novartis Agreement
February 3, 2015 8:08 AM ESTArray Biopharma (NASDAQ: ARRY) reported Q2 EPS of ($0.06), $0.12 better than the analyst estimate of ($0.18). Revenue for the quarter came in at $26.92 million versus the consensus estimate of $10.2 million.
Array announced today that Michael Carruthers, Chief Financial Officer (CFO), will be leaving Array to pursue an opportunity in the biopharmaceutical industry. The board and executive team thank Mr. Carruthers for his leadership and contributions to the success of Array. Dave Horin, CPA, a managing partner at Chord Advisers, has been appointed as interim CFO, and a search is underway for a CFO replacement to... More
